Amarin reported $634.08M in Assets for its fiscal quarter ending in September of 2026.





Assets Change Date
AbbVie USD 147.68B 12.57B Sep/2026
Alnylam Pharmaceuticals USD 7.99B 2.44B Sep/2026
Amarin USD 634.08M 9.72M Sep/2026
AstraZeneca USD 119.92B 4.09B Sep/2026
BioCryst Pharmaceuticals USD 591.07M 33.22M Sep/2026
DBV Technologies USD 215.4M 7.8M Sep/2026
GlaxoSmithKline GBP 71.7B 9.96B Sep/2026
Halozyme Therapeutics USD 3.47B 895.94M Sep/2026
Heron Therapeutics USD 230.45M 21.81M Sep/2026
Ionis Pharmaceuticals USD 2.91B 81.91M Sep/2026
Nektar Therapeutics USD 763.27M 482.86M Mar/2026
Neurocrine Biosciences USD 5.63B 268.3M Sep/2026
Novartis USD 117.15B 4.88B Sep/2026